• Novartis' CML drug hits PhIII targets pharmatimes
    August 26, 2020
    Novartis' Phase III ASCEMBL study has met its primary goal showing that asciminib was superior to bosutinib in inducing a major molecular response (MMR) in patients with a certain from of chronic myeloid leukaemia (CML).
PharmaSources Customer Service